On June 3, 2021 Kyowa Kirin Co., Ltd. (President and CEO: Masashi Miyamoto, "Kyowa Kirin", TSE: 4151) reported that it will make a change in its organization as of July 1, 2021 (Press release, Kyowa Hakko Kirin, JUN 3, 2021, View Source [SID1234583433]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Outline of the change:
R&D Quality Assurance Department will be newly established within the Quality Division.

Purpose of the organizational change:
By integrating quality assurance activities of clinical and non-clinical studies into the Quality Division, execute drug development and post-marketing clinical trials activities in a more reliable organizational structure.